In this issue:
All-cause mortality for torsemide vs. furosemide after HF hospitalisation
Is exercise capacity limited by elevated PCWP in HFPEF?
Association of anthracycline exposure with HF
Sociodemographic differences in HFREF medical therapy
Effects of His bundle pacing on HF symptoms and exercise capacity
Cost effectiveness of immediate dapagliflozin in patients with HF history
Association of PCSK9 loss-offunction variants with HF risk
Transcriptomic and proteomic profiles identify HF patients with potential for myocardial recovery
Prognostic implications of PVP-assessed post-discharge haemodynamic congestion after acute HF
Sex differences in response to dapagliflozin for HF across the EF spectrum
Please login below to download this issue (PDF)